Research programme: malaria vaccines - Leidos Holdings/National Institute of Allergy and Infectious Diseases

Drug Profile

Research programme: malaria vaccines - Leidos Holdings/National Institute of Allergy and Infectious Diseases

Alternative Names: Circumsporozoite protein-based vaccine - Leidos/NIAID; CSP antigen - Leidos/NIAID; Plasmodium falciparum-based vaccines - Leidos/NIAID; Px 533; Reticulocyte-binding homologue 5-based vaccine - Leidos/NIAID; Rh5 antigen - Leidos/NIAID

Latest Information Update: 14 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Leidos Holdings
  • Developer Leidos Holdings; National Institute of Allergy and Infectious Diseases
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 16 Mar 2015 Pfenex plans a phase I trial for malaria in USA
  • 29 Oct 2013 Preclinical development is ongoing in USA
  • 27 Sep 2013 Science Applications International Corporation changes its name to Leidos Holdings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top